Evidence map›Paper›PMID 41826407›Full record

ArticleScientific reports2026

Assessment of Mycobacterium tuberculosis dodecin scaffold as a multimerization platform on the immunogenicity of HPV L2 antigens.

Ecem Kaplan, Filipe Colaco Mariz, Xueer Zhao, Michelle Nessling, Lara Veitl, Yueru Zhang, Heiko Weyd, Martin Müller

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ecem KaplanTumorvirus-specific Vaccination Strategies, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Filipe Colaco MarizTumorvirus-specific Vaccination Strategies, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Xueer ZhaoTumorvirus-specific Vaccination Strategies, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Michelle NesslingCentral Unit Electron Microscopy, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Lara VeitlTumorvirus-specific Vaccination Strategies, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Yueru ZhangTumorvirus-specific Vaccination Strategies, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Heiko WeydTumorvirus-specific Vaccination Strategies, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Martin MüllerTumorvirus-specific Vaccination Strategies, German Cancer Research Center (DKFZ), Heidelberg, Germany. martin.mueller@dkfz-heidelberg.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human papillomavirus infection, the primary cause of cervical cancer (the fourth most common cancer in women), is preventable through prophylactic HPV vaccines. As an alternative to current HPV vaccines, all based on a cocktail of L1 virus-like particles (VLPs) from multiple HPV types, the L2 capsid protein offers cross-protection via a conserved epitope residing at the N-terminus between residues 20-38. The Trx-L2

Indexed as

Antigens, ViralBacterial ProteinsCapsid ProteinsHuman Papillomavirus VirusesMycobacterium tuberculosisOncogene Proteins, ViralPapillomavirus VaccinesAnimalsEpitopesFemaleHumansMiceNanoparticlesNanovaccinesPapillomavirus InfectionsProtein MultimerizationAntigens, ViralBacterial ProteinsCapsid ProteinsEpitopesNanovaccinesOncogene Proteins, ViralPapillomavirus VaccinesProtein Subunit Vaccines

Identifiers

PMID41826407
PMCPMC12992684

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.